Brought to you by 
Allergan licenses Serenity's Phase III Ser120; agreement later terminated
27 Sep 2017
Executive Summary
Allergan Inc. licensed exclusive worldwide development, manufacturing, and marketing rights to four-year-old Serenity Pharmaceuticals LLC's (reformulates patented therapeutics) Ser120 (low-dose desmopressin), which is in Phase III for nocturia. The agreement covers all indications except primary nocturnal enuresis (pediatric bedwetting), but Allergan has the right of first refusal to negotiate a license for that therapeutic use.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan licenses Serenity's Phase III Ser120; agreement later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice